Last reviewed · How we verify

cetuximab, capecitabine — Competitive Intelligence Brief

cetuximab, capecitabine (cetuximab, capecitabine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EGFR inhibitor, thymidylate synthase inhibitor. Area: Oncology.

phase 3 EGFR inhibitor, thymidylate synthase inhibitor EGFR, thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

cetuximab, capecitabine (cetuximab, capecitabine) — Institute of Oncology Ljubljana. Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), while capecitabine is a prodrug that is converted into 5-fluorouracil, a thymidylate synthase inhibitor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
cetuximab, capecitabine TARGET cetuximab, capecitabine Institute of Oncology Ljubljana phase 3 EGFR inhibitor, thymidylate synthase inhibitor EGFR, thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EGFR inhibitor, thymidylate synthase inhibitor class)

  1. Institute of Oncology Ljubljana · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). cetuximab, capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/cetuximab-capecitabine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: